Cadaverine Tartrate

Cadaverine Tartrate

SCHEMBL28136011

CC(=O)O.CC(=O)O.O=C(O)C(O)C(O)C(=O)O

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.77
FFAR3 O14843 1/20 0.54
LCK P06239 1/20 0.54
FYN P06241 1/20 0.54
TP53 P04637 1/20 0.50
NFKB1 P19838 1/20 0.42
CYP2C19 P33261 1/20 0.42
CYP2C9 P11712 1/20 0.39
PDE4A P27815 1/20 0.39
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.35
THRB P10828 1/20 0.35
RECQL P46063 1/20 0.35
OR51E2 Q9H255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cadaverine Tartrate SCHEMBL305065 1.00 TSHR (0.77) TSHRFFAR3LCKFYNTP53
Cadaverine Tartrate SCHEMBL11877140 0.96 TSHR (0.71) TSHRFFAR3LCKFYNTP53
Cadaverine Tartrate SCHEMBL28125338 0.96 TSHR (0.71) TSHRFFAR3LCKFYNTP53
Cadaverine Tartrate SCHEMBL11052134 0.96 TSHR (0.71) TSHRFFAR3LCKFYNTP53
Cadaverine Tartrate SCHEMBL2085067 0.92 TSHR (0.77) TSHRFFAR3LCKFYNTP53
Cadaverine Tartrate SCHEMBL3972247 0.92 TSHR (0.77) TSHRFFAR3LCKFYNTP53
Cadaverine Tartrate SCHEMBL3972251 0.92 TSHR (0.77) TSHRFFAR3LCKFYNTP53
Cadaverine Tartrate SCHEMBL10709622 0.90 TSHR (0.62) TSHRFFAR3LCKFYNTP53
Cadaverine Tartrate SCHEMBL42202 0.89 TSHR (0.71) TSHRFFAR3LCKFYNTP53
Cadaverine Tartrate SCHEMBL10319920 0.89 TSHR (0.71) TSHRFFAR3LCKFYNTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106614888-A Compounded enzyme preparation of tough biscuit and preparation method of compounded enzyme preparation 四川新华扬山野生物有限公司 2017-05-10 CN claimed
CN-106509017-A Special compound enzyme preparation for crisp biscuits and preparation method thereof 武汉新华扬生物股份有限公司 2017-03-22 CN claimed
US-20260125620-A1 AMPHOTERICALLY-MODIFIED TRIALKYLENE TETRAMINE ETHOXYLATES FOR IMPROVED STAIN REMOVAL OF LAUNDRY DETERGENTS BASF SE (DE) 2026-05-07 US disclosed
US-20260125623-A1 PROCESS FOR MAKING A GRANULE OR POWDER CONTAINING A COMPLEXING AGENT BASF SE (DE) 2026-05-07 US disclosed
WO-2026087264-A1 PROCESS FOR MAKING A POWDER OR GRANULE BASF SE (DE) 2026-04-30 WO disclosed
EP-4263777-B1 BIODEGRADABLE POLYMERS BASF SE (DE) 2026-04-22 EP disclosed
EP-4716735-A1 SOLID DETERGENT FORMULATION BASF SE (DE) 2026-04-01 EP disclosed
EP-4716734-A1 SOLID COMPOSITION COMPRISING AT LEAST ONE ORGANIC CHEMICAL COMPOUND AND AT LEAST ONE CERAMIC OXIDE BASF SE (DE) 2026-04-01 EP disclosed
US-20260078318-A1 GRANULES OF MGDA AND (METH)ACRYLIC ACID HOMO- OR CO-POLYMER; PROCESS FOR MAKING THE SAME BASF SE (DE) 2026-03-19 US disclosed
EP-4705374-A1 BIODEGRADABLE POLYOL PROPOXYLATES, THEIR PREPARATION, USES, AND COMPOSITIONS COMPRISING THEM BASF SE (DE) 2026-03-11 EP disclosed
EP-4695321-A1 VINYL ACETATE HAVING LOW DEUTERIUM CONTENT BASF SE (DE) 2026-02-18 EP disclosed
WO-2022136409-A1 AMPHIPHILIC ALKOXYLATED POLYALKYLENE IMINES OR ALKOXYLATED POLYAMINES BASF SE (DE) 2022-06-30 WO disclosed
WO-2022136408-A1 NEW ALKOXYLATED POLYALKYLENE IMINES OR ALKOXYLATED POLYAMINES BASF SE (DE) 2022-06-30 WO disclosed
WO-2022128684-A1 BIODEGRADABLE POLYMERS BASF SE (DE) 2022-06-23 WO disclosed
US-20220154112-A1 PROCESS FOR MAKING A GRANULE OR POWDER BASF SE (DE) 2022-05-19 US disclosed
EP-3947622-A1 PROCESS FOR MAKING A GRANULE OR POWDER BASF SE (DE) 2022-02-09 EP disclosed
CN-113966383-A Cleaning composition and use thereof 巴斯夫欧洲公司 2022-01-21 CN disclosed
CN-106614888-A Compounded enzyme preparation of tough biscuit and preparation method of compounded enzyme preparation 四川新华扬山野生物有限公司 2017-05-10 CN disclosed
CN-106509017-A Special compound enzyme preparation for crisp biscuits and preparation method thereof 武汉新华扬生物股份有限公司 2017-03-22 CN disclosed
CN-106490178-A A kind of coagulator made suitable for bean curd and preparation method thereof 连云港日丰钙镁有限公司 2017-03-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078318-A1 GRANULES OF MGDA AND (METH)ACRYLIC ACID HOMO- OR CO-POLYMER; PROCESS FOR MAKING THE SAME SLC6A9, MVD, PGD TSHR 3857/4885FFAR3 3838/4885LCK 3786/4885
US-20260125620-A1 AMPHOTERICALLY-MODIFIED TRIALKYLENE TETRAMINE ETHOXYLATES FOR IMPROVED STAIN REMOVAL OF LAUNDRY DETERGENTS MPEG1, PHOSPHO1, EPN1 TSHR 2393/4885FFAR3 3238/4885LCK 1169/4885
US-20260125623-A1 PROCESS FOR MAKING A GRANULE OR POWDER CONTAINING A COMPLEXING AGENT SLC6A9, GGCT, SLC6A5 TSHR 4299/4885FFAR3 4277/4885LCK 3900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.